Welcome to our dedicated page for Kezar Life Sciences news (Ticker: KZR), a resource for investors and traders seeking the latest updates and insights on Kezar Life Sciences stock.
Kezar Life Sciences, Inc. (Nasdaq: KZR) is a clinical-stage biotechnology company dedicated to discovering and developing novel small molecule therapeutics to address unmet medical needs in autoimmunity and cancer. Founded in 2015 and headquartered in South San Francisco, California, Kezar focuses on creating therapies that can significantly improve patient outcomes.
The company's lead product candidate, Zetomipzomib (KZR-616), is a selective immunoproteasome inhibitor currently under clinical investigation. Zetomipzomib is being tested in Phase 2 trials for five autoimmune diseases, including lupus nephritis, autoimmune hemolytic anemia, immune thrombocytopenia, dermatomyositis, and polymyositis. In addition, Phase 1b/2 trials are underway for systemic lupus erythematosus and lupus nephritis, making it a promising candidate for treating multiple chronic immune-mediated diseases.
Kezar's preclinical pipeline also includes another selective immunoproteasome inhibitor, tentatively named KZR-TBD, aimed at treating oncology and autoimmune conditions. These efforts highlight Kezar's commitment to exploring innovative solutions for complex diseases.
Recently, Kezar Life Sciences has achieved significant milestones. Notably, in collaboration with Everest Medicines, the company received approval from China's National Medical Products Administration (NMPA) for the investigational new drug (IND) application for the Phase 2b PALIZADE trial of zetomipzomib in patients with lupus nephritis. This global, placebo-controlled trial will evaluate the efficacy and safety of zetomipzomib, marking Kezar's expansion into the Asian market.
Financially, Kezar Life Sciences continues to secure partnerships and funding to support its ambitious research and development goals. The company's strategic collaborations, like the one with Everest Medicines, enhance its ability to reach more patients and broaden its geographical footprint.
For more information, visit the company's official website at www.kezarlifesciences.com.
Kezar Life Sciences (Nasdaq: KZR), a clinical-stage biotech firm, announced a nonqualified stock option grant to purchase 80,000 shares at $0.71 per share.
The stock option, granted to a new employee on June 3, 2024, is in line with Nasdaq Listing Rule 5635(c)(4). The grant is part of Kezar's strategy to attract top talent.
The options will vest over four years: 25% after the first year, with the remainder vesting monthly. This grant is material to the individual’s employment agreement and is part of Kezar's 2022 Inducement Plan.
Kezar Life Sciences, a clinical-stage biotechnology company listed on Nasdaq (KZR), announced that its CEO, Chris Kirk, will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 5, 2024, at 12:30 pm ET in New York. The company focuses on developing novel small molecule therapeutics for immune-mediated diseases and cancer. The event will be webcasted live and available on Kezar's website for 90 days post-event.
Kezar Life Sciences, Inc. reported its first quarter 2024 financial results and business update, including progress in clinical trials for zetomipzomib in lupus nephritis and autoimmune hepatitis, and dose expansion for KZR-261 in melanoma. Cash, cash equivalents, and marketable securities totaled $179.8 million. R&D expenses decreased to $17.2 million, while G&A expenses increased to $6.5 million. Net loss was $21.7 million for the quarter.
Kezar Life Sciences, Inc. granted two employees nonqualified stock options to purchase 164,000 shares of common stock at $0.84 per share under NASDAQ Listing Rule 5635(c)(4). The options will vest over four years, with 25% on the first anniversary and 1/48th monthly thereafter, contingent on continued employment.
FAQ
What is the current stock price of Kezar Life Sciences (KZR)?
What is the market cap of Kezar Life Sciences (KZR)?
What is Kezar Life Sciences focused on?
What is Zetomipzomib (KZR-616)?
What clinical trials are currently underway for Zetomipzomib?
Where is Kezar Life Sciences headquartered?
What significant recent achievements has Kezar Life Sciences made?
What are Kezar's preclinical products?
When was Kezar Life Sciences founded?
Who is Kezar Life Sciences' regional partner in Asia?
How can I get more information about Kezar Life Sciences?
What is the PALIZADE trial?
